Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients
The American Journal of Psychiatry
Fecha de publicación: 12 January 2018
Autores: Marin M. Jukić, Ph.D., Tore Haslemo, Ph.D., Espen Molden, Ph.D., Magnus Ingelman-Sundberg, Ph.D.
Background: The antidepressant escitalopram is predominantly metabolized by the polymorphic CYP2C19 enzyme. The authors investigated the effect of CYP2C19 genotype on exposure and therapeutic failure of escitalopram in a large patient population.